Follow
Feb. 1, 2021
Bayer, one of the largest pharmaceutical companies in the world, has led a $40 million investment in an Israeli start-up developing solutions for allergies and food sensitivities using artificial intelligence and protein engineering.
The start-up, called Ukko, is focusing on two strategies. One is the growing of gluten without its allergenic components in plants such as wheat and corn, the other being the development of a medication that will “re-educate” the immune system so that it can overcome a peanut allergy. If the company succeeds in these ventures, this will have great significance for people with celiac disease or for people facing life-threatening peanut allergies.